Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD).

PubWeight™: 1.07‹?› | Rank: Top 10%

🔗 View Article (PMC 4030641)

Published in Sci Transl Med on April 23, 2014

Authors

Stephen P Fink1, Mai Yamauchi, Reiko Nishihara, Seungyoun Jung, Aya Kuchiba, Kana Wu, Eunyoung Cho, Edward Giovannucci, Charles S Fuchs, Shuji Ogino, Sanford D Markowitz, Andrew T Chan

Author Affiliations

1: Department of Medicine and Case Comprehensive Cancer Center, Case Western Reserve University and University Hospitals Case Medical Center, 10900 Euclid Avenue, Cleveland, OH 44106, USA.

Articles citing this

TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science (2015) 2.40

Review Article: The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-neoplastic Diseases in the Era of Precision Medicine. Epidemiology (2016) 1.89

Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology (2015) 1.35

Drug repurposing in oncology-patient and health systems opportunities. Nat Rev Clin Oncol (2015) 1.25

Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn (2015) 0.94

Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control (2015) 0.94

Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prev Res (Phila) (2016) 0.93

Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol (2016) 0.86

Chemo/Dietary prevention of cancer: perspectives in China. J Biomed Res (2014) 0.83

Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet (2016) 0.83

Prostaglandin E2 Activates YAP and a Positive-signaling Loop to Promote Colon Regeneration Following Colitis but Also Carcinogenesis in Mice. Gastroenterology (2016) 0.79

Lipidome in colorectal cancer. Oncotarget (2016) 0.79

Cancer prevention and control: alarming challenges in China. Natl Sci Rev (2015) 0.79

Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. Gut (2015) 0.79

Biomarker-directed Targeted Therapy in Colorectal Cancer. J Dig Cancer Rep (2015) 0.78

The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism. J Pharmacol Exp Ther (2015) 0.78

Colorectal Cancer Epidemiology in the Nurses' Health Study. Am J Public Health (2016) 0.77

Inverse expression of prostaglandin E2-related enzymes highlights differences between diverticulitis and inflammatory bowel disease. Dig Dis Sci (2015) 0.77

Prediagnosis aspirin use and outcomes in a prospective cohort of esophageal cancer patients. Therap Adv Gastroenterol (2016) 0.76

Colonic Saturated Fatty Acid Concentrations and Expression of COX-1, but not Diet, Predict Prostaglandin E2 in Normal Human Colon Tissue. Nutr Cancer (2016) 0.75

Post-colonoscopy colorectal cancer: the key role of molecular pathological epidemiology. Transl Gastroenterol Hepatol (2017) 0.75

ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. Trials (2017) 0.75

Gastroprotective [6]-Gingerol Aspirinate as a Novel Chemopreventive Prodrug of Aspirin for Colon Cancer. Sci Rep (2017) 0.75

Sex-Specific Associations between Particulate Matter Exposure and Gene Expression in Independent Discovery and Validation Cohorts of Middle-Aged Men and Women. Environ Health Perspect (2016) 0.75

Articles cited by this

The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem (2009) 40.90

Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res (2004) 25.98

Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc (1993) 19.40

Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. Biotechnol Lett (2004) 18.55

qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol (2007) 16.15

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet (2010) 11.00

Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04

Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet (2007) 7.11

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet (2012) 5.81

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet (2012) 4.85

Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology (1996) 4.37

Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88

A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med (2004) 3.46

The role of aspirin in cancer prevention. Nat Rev Clin Oncol (2012) 2.94

Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology (2007) 2.73

15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem (2004) 2.55

Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol (2012) 2.45

15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A (2004) 2.42

15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.41

Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med (2013) 2.33

Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA (2011) 2.28

Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA (2013) 2.26

Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) (2011) 2.03

Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology (2012) 1.77

15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A (2009) 1.65

Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26

Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation. Carcinogenesis (2011) 1.02

Aspirin and colorectal cancer: back to the future. Clin Cancer Res (2013) 0.95

Genetic variation in 15-hydroxyprostaglandin dehydrogenase and colon cancer susceptibility. PLoS One (2013) 0.91

Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut (2011) 0.90

Aspirin in prevention of sporadic colorectal cancer: current clinical evidence and overall balance of risks and benefits. Recent Results Cancer Res (2013) 0.85

Differential effects of aspirin before and after diagnosis of colorectal cancer. JAMA (2013) 0.84

Colonic 15-PGDH levels are stable across distance and time and are not perturbed by aspirin intervention. Dig Dis Sci (2013) 0.83

COX-2 active agents in the chemoprevention of colorectal cancer. Recent Results Cancer Res (2013) 0.82

15-hydroxyprostaglandin dehydrogenase in colorectal mucosa as a potential biomarker for predicting colorectal neoplasms. J Korean Med Sci (2013) 0.81

Articles by these authors

The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 50.94

The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12

Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18

Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24

Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr (2006) 10.95

Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39

Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04

Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78

Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med (2013) 7.72

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47

Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst (2006) 7.19

Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension (2007) 6.99

Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26

CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24

Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00

Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res (2011) 5.97

Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95

Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med (2006) 5.24

Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol (2006) 5.22

Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14

A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89

ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst (2009) 4.72

Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn (2006) 4.68

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54

Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature (2010) 4.53

Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48

Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med (2003) 4.40

Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 4.37

The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One (2008) 4.32

Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27

Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol (2012) 4.22

Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13

A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology (2013) 4.06

Comparison of risk factors for colon and rectal cancer. Int J Cancer (2004) 4.03

Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01

CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn (2006) 3.98

Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst (2006) 3.96

Association of nut consumption with total and cause-specific mortality. N Engl J Med (2013) 3.94

Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88

Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology (2011) 3.84

Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst (2005) 3.73

Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69

Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut (2012) 3.67

Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn (2007) 3.56

Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med (2007) 3.55

Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst (2003) 3.54

Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature (2012) 3.54

A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst (2008) 3.54

Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation (2003) 3.50

A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst (2004) 3.49

A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med (2004) 3.46

Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol (2006) 3.41

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol (2012) 3.36

Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34

Patients' perceptions of quality of care for colorectal cancer by race, ethnicity, and language. J Clin Oncol (2005) 3.30

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 3.24

Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. Lancet Oncol (2008) 3.23

Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst (2005) 3.22